The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Masitinib mesylate in imatinib-resistant advanced GIST: A randomized phase II trial.
Antoine Adenis
Honoraria - AB Science
Research Funding - AB Science
Axel Le Cesne
Honoraria - AB Science
Research Funding - AB Science
Binh Bui Nguyen
Honoraria - AB Science
Research Funding - AB Science
Olivier Bouche
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - AB Science
Julien Domont
No relevant relationships to disclose
Isabelle Ray-Coquard
No relevant relationships to disclose
Nicolas Penel
No relevant relationships to disclose
Aurore Blesius
No relevant relationships to disclose
Francois Montestruc
Employment or Leadership Position - AB Science
Stock Ownership - AB Science
Alain Moussy
Employment or Leadership Position - AB Science
Stock Ownership - AB Science
Olivier Hermine
Employment or Leadership Position - AB Science
Consultant or Advisory Role - AB Science
Stock Ownership - AB Science
Research Funding - AB Science
Jean-Yves Blay
Honoraria - AB Science
Research Funding - AB Science